Osteoarthritis

Mundipharma Extends Strategic Partnership with Kolon Life Science to Commercialise Invossa(R)-k in Saudi Arabia and United Arab Emirates

Retrieved on: 
Tuesday, June 26, 2018
Biology, Health, Medicine, Arthritis, Osteoarthritis, RTT, Therapy, Gene therapy for osteoarthritis, Gene therapy

SINGAPORE, June 26, 2018 /PRNewswire/ -- Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to marketInvossa-K in Saudi Arabia and United Arab Emirates.

Key Points: 
  • SINGAPORE, June 26, 2018 /PRNewswire/ -- Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to marketInvossa-K in Saudi Arabia and United Arab Emirates.
  • The agreement builds on the existing co-promotion agreement between the two companies in Korea signed in April 2017.
  • "We are delighted to extend our relationship with Kolon Life Science and Invossa-Kinternationally," said Raman Singh, CEO, Mundipharma.
  • Kolon Life Science has been developing innovative cell and gene therapies including Invossa-K the world's first cell-mediated gene therapy for osteoarthritis, since its founding in 2000.

Ampio Updates Scientific presentations and publications on Ampion™

Retrieved on: 
Tuesday, May 22, 2018
Medicine, Health, Clinical medicine, RTT, Skeletal disorders, Medical emergencies, Intensive care medicine, Arthritis, Osteoarthritis, Wound, Sepsis, Inflammation

Therefore,Ampion which contains NAK is a useful therapeutic in medical conditions where inflammation is prevalent such as trauma,osteoarthritis,sepsis, and wound healing."

Key Points: 
  • Therefore,Ampion which contains NAK is a useful therapeutic in medical conditions where inflammation is prevalent such as trauma,osteoarthritis,sepsis, and wound healing."
  • In the severe KL4 subset, treatment with Ampion resulted in a lower rate of TKA compared to saline vehicle arm (40% vs. 83%).
  • This result supports previous findings that the treatment effect of Ampion is greatest in patients with the more severe disease.
  • Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

CurveBeam Announces FDA 510(k) Clearance for LineUP Weight Bearing Multi-Extremity CT System

Retrieved on: 
Monday, May 14, 2018
Medicine, RTT, Skeletal disorders, Health, Clinical medicine, Arthritis, Osteoarthritis, Orthopedic surgery, Osteochondritis dissecans

WARRINGTON, Pa., May 14, 2018 /PRNewswire/ -- CurveBeam announced it has received FDA 510(k) clearance for its LineUP Multi-extremity weight bearing CT system.

Key Points: 
  • WARRINGTON, Pa., May 14, 2018 /PRNewswire/ -- CurveBeam announced it has received FDA 510(k) clearance for its LineUP Multi-extremity weight bearing CT system.
  • "CurveBeam continues to elevate the standard of care for orthopedic extremity imaging, and introduction of the LineUP device is another solid step upwards," CurveBeam President & CEO Arun Singh said.
  • Published research also suggests three-dimensional weight bearing views of the knees could be instrumental in early detection of osteoarthritis.
  • CurveBeam introduced the pedCAT system, which permits bilateral weight bearing scans of the feet and ankles in 2012.

Launch of New National Osteoarthritis Awareness Campaign: "StandUP2OA" Has Unique Focus on Disease Prevention

Retrieved on: 
Tuesday, May 8, 2018
Skeletal disorders, RTT, Health, Medicine, Arthritis, Rheumatology, Aging-associated diseases, Osteoarthritis, Health care

CHAPEL HILL, N.C., May 8, 2018 /PRNewswire/ -- Today, 30million Americans nearly 1 in10 adults have osteoarthritis (OA), a leading cause of disability.

Key Points: 
  • CHAPEL HILL, N.C., May 8, 2018 /PRNewswire/ -- Today, 30million Americans nearly 1 in10 adults have osteoarthritis (OA), a leading cause of disability.
  • Of the 100 different types of arthritis, osteoarthritis is the most common and isa serious disease that mainly affects joints in the hands, knees and hips in adults.
  • In response to this growing public health epidemic the Osteoarthritis Action Alliance (OAAA) is launching a new comprehensive campaign StandUp2OA -- focused on osteoarthritis awareness and prevention.
  • To help raise awareness about the StandUp2OA campaign and osteoarthritis prevention, the OAAA has developed free tools, resources and infographics that are specific to OAand empower patients, health care providers, policymakers and communities to promote:

Activity Trackers Paired with Professional Coaching Significantly Help Increase Physical Activity in Patients with Knee Osteoarthritis

Retrieved on: 
Monday, April 30, 2018
Medicine, Skeletal disorders, RTT, Health, Rheumatology, Aging-associated diseases, Clinical medicine, Arthritis, Osteoarthritis, Knee, Knee arthritis, Pentosan polysulfate

For patients who have knee osteoarthritis, physical activity is an essential first-line treatment.

Key Points: 
  • For patients who have knee osteoarthritis, physical activity is an essential first-line treatment.
  • However, only 13% of patients meet the activity recommendation of 150 minutes or more per week.
  • A total of 61 patients with knee osteoarthritis participated in the study and were assessed to see if the program led to increased daily activity and reduced sedentary time.
  • While the study showed an increase in physical activity, it did not show a reduction in the time spent in sedentary activities, like sitting.

Veterinary Pain Management Market - Global Forecast to 2023

Retrieved on: 
Monday, April 30, 2018
Pain, Perception, Acute pain, Hepatotoxins, RTT, Arthritis, Osteoarthritis, Pain management, Nonsteroidal anti-inflammatory drug, Opioid

The "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic)), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic)), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
  • The veterinary pain management market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.
  • By application, the veterinary pain management market has been segmented into joint pain, postoperative pain, cancer, and other applications.
  • By animal type, the global veterinary pain management market is segmented into companion and livestock animals.

Veterinary Pain Management Market Worth 1.66 Billion USD by 2023

Retrieved on: 
Friday, April 20, 2018
Pain, Perception, Medicine, RTT, Skeletal disorders, Acute pain, Hepatotoxins, Pain management, Osteoarthritis, Nonsteroidal anti-inflammatory drug, Arthritis, Opioid

According to a new market research report "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy)) - Global Forecast to 2023", published by MarketsandMarkets, the market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.

Key Points: 
  • According to a new market research report "Veterinary Pain Management Market by Product (Drugs (NSAIDs, Opioids), Device (Laser, Electromagnetic), Application (Osteoarthritis, Cancer), Animal Type (Dog, Cat, Horse, Cattle), Distribution Channel (Hospital, Pharmacy)) - Global Forecast to 2023", published by MarketsandMarkets, the market is projected to reach USD 1.66 Billion by 2023 from USD 1.13 Billion in 2018, at a CAGR of 8.0% during the forecast period.
  • Based on application, the Veterinary Pain Management Market has been segmented into joint pain, postoperative pain, cancer, and other applications.
  • In 2017, joint pain held the largest share of the Veterinary Pain Management Market.
  • Global Veterinary Pain Management Market has been studied for North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa.

Musculoskeletal Disorders Pipeline Database 2018: Osteoporosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Ankylosing Spondylitis

Retrieved on: 
Wednesday, April 18, 2018
Medicine, RTT, Rheumatology, Arthritis, Anatomy, Health, Skeletal disorders, Autoimmune diseases, Rheumatism, Osteoarthritis, Ankylosing spondylitis, Rheumatoid arthritis

Musculoskeletal Disorders Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.

Key Points: 
  • Musculoskeletal Disorders Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • The database provides Musculoskeletal Disorders pipeline products by the company.

Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum

Retrieved on: 
Wednesday, April 18, 2018
Biotechnology, Biology, Nature, Arthritis, Osteoarthritis, RTT, Biopharmaceutical

Symic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology.

Key Points: 
  • Symic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology.
  • These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix.
  • Symic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting the prevention of peripheral vein graft failure.
  • In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

Merck KGaA, Darmstadt, Germany, Presents New Osteoarthritis Data at OARSI 2018 World Congress

Retrieved on: 
Wednesday, April 18, 2018
Health, Medicine, Skeletal disorders, RTT, Arthritis, Osteoarthritis, Aging-associated diseases, Rheumatology, Chronic condition, Therapy, Merck Group

The presence of Merck KGaA, Darmstadt, Germany at OARSI reflects the company's dedication to helping optimize outcomes for patients living with chronic progressive diseases, with the goal of developing novel disease-modifying therapies for osteoarthritis (OA).

Key Points: 
  • The presence of Merck KGaA, Darmstadt, Germany at OARSI reflects the company's dedication to helping optimize outcomes for patients living with chronic progressive diseases, with the goal of developing novel disease-modifying therapies for osteoarthritis (OA).
  • Data of note includes an oral presentation of the three-year analysis of FORWARD, a five-year, multicenter Phase II study of sprifermin in OA of the knee.
  • "Our intent is to provide true advancement to the field of osteoarthritis by developing therapeutic options with disease-modifying potential."
  • Accepted abstracts at the OARSI 2018 World Congress include: